MFT
EDIT icon

Moisand Fitzgerald Tamayo’s Editas Medicine EDIT Stock Holding History

Moisand Fitzgerald Tamayo’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100
Closed -$3K – 536
2021
Q4 		$3K Hold
100
– – ﹤0.01% 322
2021
Q3 		$4K Hold
100
– – ﹤0.01% 307
2021
Q2 		$6K Buy
+100
New +$3.69K ﹤0.01% 301

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Moisand Fitzgerald Tamayo's EDIT Position: Q1 2022 in Review

Moisand Fitzgerald Tamayo sold out of Editas Medicine (EDIT) in Q1 2022, closing a stake of 100 shares — an estimated $3K sold.

Moisand Fitzgerald Tamayo first reported a position in EDIT in Q2 2021 and held it in 3 quarters. The position peaked at $6K in Q2 2021. 256 funds tracked by Wall St. Rank hold EDIT as of Q1 2022.

  • Moisand Fitzgerald Tamayo reported no remaining Editas Medicine position as of Q1 2022 after selling out during the quarter.
  • Moisand Fitzgerald Tamayo sold 100 Editas Medicine shares in Q1 2022, an estimated $3K.
  • Moisand Fitzgerald Tamayo first reported a position in Editas Medicine in Q2 2021 and held it in 3 quarters.
  • Moisand Fitzgerald Tamayo's Editas Medicine position peaked at $6K in Q2 2021.
  • 256 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2022.

Based on Moisand Fitzgerald Tamayo's 13F filing for Q1 2022, filed 29 Apr 2022.